A Randomized Trial of Protocolized Diuretic Therapy Compared to Standard Care in Emergency Department Patients with Acute Heart Failure
September 1, 2021
VUMC, NIH launch clinical trial to test novel therapies to protect host tissue against COVID-19
July 29, 2021
https://news.vumc.org/2021/07/26/vumc-nih-launch-clinical-trial-to-test-novel-therapies-to-protect-host-tissue-against-covid-19/
Vanderbilt University Medical Center researchers, supported by the National Institutes of Health (NIH), are leading a nationwide clinical trial to explore the safety and effectiveness of a group of novel drugs designed to protect patients hospitalized with COVID-19 at high risk of poor outcomes.
The new trial has enrolled its first patient.
VUMC to lead national study to treat severe COVID complications
May 6, 2021
https://news.vumc.org/2021/05/06/vumc-to-lead-national-study-to-treat-severe-covid-complications/
The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.
Collins takes on new VCC, IMPH leadership roles
February 24, 2021
https://news.vumc.org/2021/02/24/collins-takes-on-new-vcc-imph-leadership-roles/
Sean Collins, MD, MSci, professor of Emergency Medicine, has taken on new leadership roles in the Vanderbilt Coordinating Center (VCC) and the Vanderbilt Institute for Medicine and Public Health (IMPH).
Dr. Sean Collins and colleagues receives VU Trans-Institutional Programs (TIPs) Funding
June 30, 2020
Posted in
Vanderbilt’s Trans-Institutional Programs (TIPs) investments fund programs devoted to discovery and learning with an “interdisciplinary” approach that addresses society’s most pressing problems. It's a centerpiece of the university’s Academic Strategic Plan.
This year, TIPs has funded the project Soldier-Inspired Innovation Incubator for Discovering Research-Based Solutions in Vanderbilt Re-Investment Awards (VRA) category. Project faculty are from the School of Engineering, College of Arts and Science, Peabody College, School of Medicine – Clinical, and Owen Graduate School of Management.
Project researcher, Sean Collin, MD, is Professor and Executive Vice Chairman for Research and Director of the Center for Emergency Care Research and Innovation at Vanderbilt University Medical Center.
Project lead, Douglas Adams, Ph.D., is Daniel F. Flowers Professor, Distinguished Professor, Chair of Civil and Environmental Engineering, and Professor of Mechanical Engineering at Vanderbilt University.
Study aims to shield health workers from COVID-19 infection
https://news.vumc.org/2020/04/02/study-aims-to-shield-health-workers-from-covid-19-infection/
Vanderbilt University Medical Center is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.
The Board of Governors of the non-profit Patient-Centered Outcomes Research Institute (PCORI) in Washington, D.C., today approved up to $50 million to fund the initiative, known as the Healthcare Worker Exposure Response and Outcomes (HERO) research program, to be led by the Duke Clinical Research Institute (DRCI).
Co-chairs of the HERO Steering Committee are Russell Rothman, MD, MPP, VUMC Senior Vice President for Population and Public Health, and Judith Currier, MD, professor of Medicine and chief of the Division of Infectious Diseases at UCLA Medical Center, Santa Monica.
Fellow steering committee member Sean Collins, MD, MSCI, professor and executive vice chair of the Department of Emergency Medicine at VUMC, will lead VUMC’s engagement in the HERO study and will serve as the site’s principal investigator. He also is a member of the protocol advisory committee.
Study aims to shield health workers from COVID-19 infection
April 2, 2020
https://news.vumc.org/2020/04/02/study-aims-to-shield-health-workers-from-covid-19-infection/
Vanderbilt University Medical Center is playing a key role in a national effort to establish a registry of U.S. health care workers and test whether the anti-malarial drug hydroxychloroquine (HCQ) will protect them, their patients and their families from COVID-19.